Table 4.

Cost analyses with the Following Assumptions: N=159 patients; ASP Plerixafor = $6,000/dose

Scenario	# (%) patients receiving plerixafor	Efficacy # (%) patients collecting >5 × 106 CD34+ cells/kg in ≤2 apheresis days	% Switch from Poor to Good	Average Cost/pt	Average Cost/pt difference from reference cohort
A) VP-16/G-CSF [reference cohort]	0	90 (57%)	n/a	$20,184 (actual)	0 (reference)
B) G-CSF + plerixafor	159 (100%)	78 (49%)	n/a	$32,760	$12,576
C) VP-16/G-CSF + plerixafor	159 (100%)	159 (100%)	100%	$32,924	$12,740
(3 doses for all)			(breakeven not possible)
D) VP-16/G-CSF + plerixafor	69 (43%)	131 (82%)	62%	$20,228	$44
(3 doses for predicted poor mobilizers)			(breakeven)
E) VP-16/G-CSF + plerixafor	159 (100%)	159 (100%)	100%	$26,924	$6,740
(2 doses for all)			(breakeven not possible)
F) VP-16/G-CSF + plerixafor	69 (43%)	124 (78%)	49%	$20,233	$49
(2 doses for predicted poor mobilizers)			(breakeven)

A. All patients receive etoposide and G-CSF, with efficacy rates, costs and complications calculated from our observed cohort.

B. All patients receive G-CSF (7 total days) and 3 doses of plerixafor, 3 days of apheresis, no levofloxacin, no etoposide, no PRBC transfusions, no Platelet transfusions, no IV antibiotics, no inpatient admissions. Median doses of plerixafor, median days of apheresis, and efficacy rates are extrapolated from published phase III data.²

C. All patients receive etoposide and G-CSF. Median 3 doses of plerixafor are given to all patients. This scenario assumes a 100% efficacy rate in converting bad to good mobilizers. Average costs/pt based on costs associated with patients who are good mobilizers + 3 doses of plerixafor for each patient.

D. All patients receive etoposide and G-CSF. Median 3 doses of plerixafor are given to predicted poor mobilizers based on first CD34 count. A breakeven analysis is performed by modeling the # of patients who would need to experience improved outcomes and thus lower resource utilization in order to offset the costs of giving plerixafor to these patients. Please see Table 7 for component costs.

E. All patients receive etoposide and G-CSF. Median 2 doses of plerixafor are given to all patients. This scenario assumes a 100% efficacy rate in converting bad to good mobilizers. Average costs /pt based on costs associated with patients who are good mobilizers + 2 doses of plerixafor for each patient.

F. All patients receive etoposide and G-CSF. Median 2 doses of plerixafor are given to predicted poor mobilizers based on first CD34 count (probability ≤0.5). A breakeven analysis is performed by modeling the # of patients who would need to experience improved outcomes and thus lower resource utilization in order to offset the costs of giving plerixafor to these patients. Please see Table 5 for component costs.